PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2013 | 3 | 3 | 213-215
Article title

Stanowisko w sprawie stosowania niepegylowanej liposomalnej doksorubicyny u chorych na chłoniaki ze współistniejącymi chorobami sercowo-naczyniowymi

Content
Title variants
EN
Consensus statement on indications for the use of non-pegylated liposomal doxorubicin in patients with lymphomas and concomitant cardiovascular diseases
Languages of publication
PL
Abstracts
Keywords
Discipline
Publisher

Journal
Year
Volume
3
Issue
3
Pages
213-215
Physical description
Contributors
  • Klinika Krążenia Płucnego i Chorób Zakrzepowo-Zatorowych, Centrum Medyczne Kształcenia Podyplomowego
  • Katedra i Klinika Hematologii, Onkologii i Chorób Wewnętrznych, Warszawski Uniwersytet Medyczny
  • I Katedra i Klinika Kardiologii, Warszawski Uniwersytet Medyczny
References
  • Curigliano G., Cardinale D., Suter T., Plataniotis G., de Azambuja E., Sandri M.T., Criscitiello C., Goldhirsch A., Cipolla C., Roila F.; ESMO Guidelines Working Group: Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann. Oncol. 2012; 23(supl. 7): vii155-66.
  • Jurczak W., Szmit S., Sobociński M., Machaczka M., Drozd-Sokołowska J., Joks M., Dzietczenia J., Wróbel T., Kumiega B., Zaucha J.M., Knopińska- Posłuszny W., Spychałowicz W., Prochwicz A., Drohomirecka A., Skotnicki A.B.: Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen – A national multicenter study. International Journal of Cardiology 2013; pii: S0167-5273(13)01558-1 [online: doi: 10.1016/j.ijcard.2013.08.033].
  • Moser E.C., Noordijk E.M., van Leeuwen F.E., le Cessie S., Baars J.W., Thomas J., Carde P., Meerwaldt J.H., van Glabbeke M., Kluin-Nelemans H.C.: Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood 2006; 107(7): 2912-9.
  • Myrehaug S., Pintilie M., Yun L., Crump M., Tsang R.W., Meyer R.M., Sussman J., Yu E., Hodgson D.C.: A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease. Blood 2010; 116: 2237-40.
  • Rigacci L., Mappa S., Nassi L., Alterini R., Carrai V., Bernardi F., Bosi A.: Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines. Hematol. Oncol. 2007; 25: 198-203.
  • Fridrik M., Petzer A., Keil F. et al.: Non-Pegylated Liposomal Encapsulated Doxorubicin Reduces Cardiotoxicity in 1st Line Treatment of Diffuse Large B-Cell Lymphoma (DLBCL). Final Results of a Randomized Trial. Blood 2011; 2676.
  • Batist G., Ramakrishnan G., Rao C.S., Chandrasekharan A., Gutheil J., Guthrie T., Shah P., Khojasteh A., Nair M.K., Hoelzer K., Tkaczuk K., Park Y.C., Lee L.W.: Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol. 2001; 19(5): 1444-54.
  • Batist G., Harris L., Azarnia N., Lee L.W., Daza-Ramirez P.: Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast prior adjuvant doxorubicin: results of a retrospective analysis. Anticancer Drugs 2006; 17(5): 587-95.
Document Type
proceedings
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-ec30528c-77fa-4dfe-9749-dd97a10277a6
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.